Getinge earnings for the third quarter of 2026 showed stronger profitability and cash generation despite modest sales growth and continued weakness in Life Science equipment. Organic net sales rose 2.1%, while adjusted EBITDA reached SEK 1,278 million, representing a 15.1% margin.

Key Takeaways

  • Organic sales increased 2.1% and order intake rose 2.6%, with pricing helping drive growth.
  • Free cash flow reached SEK 1,302 million, while leverage remained below Getinge’s internal threshold.
  • Getinge retained its 3%–5% annual organic growth guidance, but management viewed the lower end as more realistic.

Table of Contents

Getinge earnings benefit from pricing and product mix

Disciplined pricing, a greater contribution from higher-margin products and productivity improvements supported quarterly profitability. Adjusted gross profit totaled SEK 4,343 million, including approximately SEK 45 million in tariff refunds, and the adjusted gross margin improved by 2.2 percentage points.

Higher-margin products accounted for 70% of sales, while recurring revenue represented approximately two-thirds of the total. CFO Agneta Palmer said the shift toward high-margin disposables was slightly more pronounced in the quarter than the broader trend.

Over two years, Getinge’s rolling 12-month adjusted EBITDA margin improved from 12% to 15.6%. Excluding SEK 381 million in tariff refunds received during the second and third quarters of 2026, the margin was 14.5%. The company’s medium-term target remains 16%–19% by the end of 2028.

Cash generation strengthens the balance sheet

Quarterly free cash flow exceeded SEK 1 billion, reaching SEK 1,302 million. At the end of September, Getinge held approximately SEK 3.2 billion in cash and reported net debt of SEK 10.4 billion, or SEK 8.1 billion after adjusting for pension liabilities.

Leverage stood at 1.5 times adjusted EBITDA, below the company’s internal threshold of 2.5 times. Adjusted for pension liabilities, leverage was 1.1 times.

Life Science equipment remains the weak spot

Life Science recorded slight declines in both organic sales and orders. Continued weakness in washers, isolators and sterilizers outweighed growth in bioprocessing, service and sterile transfer. CEO Mattias Perjos described overall demand as stable and positive across most categories, but said large Life Science capital equipment remained sluggish.

Acute Care Therapies increased organic sales and orders, supported by ECLS therapy consumables, intra-aortic balloon pumps, cardiac assist, covered stents and EVH consumables. Surgical Workflows also posted slight organic sales growth and higher orders, with surgical tables and lights supporting order intake.

Operational constraints remain. Balloon-pump component and manpower shortages are expected to persist for the rest of 2026. Quality-related costs also remain above normal, and Palmer cautioned against expecting a larger benefit from cost reductions in the fourth quarter than in the third.

Fourth-quarter deliveries shape the outlook

Getinge left its 2026 organic sales growth forecast at 3%–5%, adjusted for the phase-out of surgical perfusion, after year-to-date growth of 2.5%. Management cited geopolitical uncertainty and fourth-quarter delivery risks, with the lower end of the range considered more realistic.

Perjos identified two key risks: slower activity in book-and-turn categories such as ECLS consumables and sterile transfer, and customers being unable to receive capital equipment before year-end. The latter could shift revenue into the first quarter of 2027.

Regulatory timing also remains uncertain. CardioSave applications have been submitted, with FDA follow-up discussions ongoing and an expected approval period of six to nine months. The U.S. ECMO process remains at the pre-submission meeting stage, with no filing update.

Conclusion

Getinge’s third quarter combined margin improvement with strong cash generation, but its unchanged annual sales outlook still depends on fourth-quarter demand and delivery execution. Life Science equipment weakness and elevated quality costs remain constraints.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.